Literature DB >> 29588757

How to Select the Most Appropriate Patient and Lesion to be Treated with a Coronary Bioresorbable Vascular Scaffold.

Charis Costopoulos1,2,3, Azeem Latib1,2, Antonio Colombo1,2.   

Abstract

Bioresorbable vascular scaffolds (BVS) are an exciting novel treatment for coronary artery disease (CAD) as their eventual resorption renders the artery free from a permanent metallic cage. Clinical trials regarding these novel devices have demonstrated promising results, although their use in this context has largely been restricted to simple lesions. More recently, BVS use has expanded to patients with more complex lesions including those with long diffuse disease, and results from several registries are awaited with regard to their efficacy in 'real-world' patients. Although any patient who requires percutaneous treatment for CAD could benefit from BVS implantation, there are certain cohorts of patients and lesions in whom BVS could be of particular benefit. In this review, we attempt to identify which patient and lesion cohort is most suitable for treatment with these novel devices.

Entities:  

Keywords:  Bioresorbable vascular scaffold; major adverse cardiac events; target lesion revascularisation

Year:  2013        PMID: 29588757      PMCID: PMC5808488          DOI: 10.15420/icr.2013.8.2.90

Source DB:  PubMed          Journal:  Interv Cardiol        ISSN: 1756-1485


  2 in total

1.  Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.

Authors:  Patrick W Serruys; Yoshinobu Onuma; Dariusz Dudek; Pieter C Smits; Jacques Koolen; Bernard Chevalier; Bernard de Bruyne; Leif Thuesen; Dougal McClean; Robert-Jan van Geuns; Stephan Windecker; Robert Whitbourn; Ian Meredith; Cecile Dorange; Susan Veldhof; Karine Miquel Hebert; Krishnankutty Sudhir; Hector M Garcia-Garcia; John A Ormiston
Journal:  J Am Coll Cardiol       Date:  2011-10-04       Impact factor: 24.094

2.  Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial.

Authors:  Roberto Diletti; Vasim Farooq; Chrysafios Girasis; Christos Bourantas; Yoshinobu Onuma; Jung Ho Heo; Bill D Gogas; Robert-Jan van Geuns; Evelyn Regar; Bernard de Bruyne; Dariusz Dudek; Leif Thuesen; Bernard Chevalier; Dougal McClean; Stephan Windecker; Robert J Whitbourn; Pieter Smits; Jacques Koolen; Ian Meredith; Xiaolin Li; Karine Miquel-Hebert; Susan Veldhof; Hector M Garcia-Garcia; John A Ormiston; Patrick W Serruys
Journal:  Heart       Date:  2012-10-31       Impact factor: 5.994

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.